Forodesine 200 mg
BCX1777-203
Phase 2 small_molecule completed
Quick answer
Forodesine 200 mg for Cutaneous T-cell Lymphoma (CTCL), is a Phase 2 program (small_molecule) at BIOCRYST PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BIOCRYST PHARMACEUTICALS INC
- Indication
- Cutaneous T-cell Lymphoma (CTCL),
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed